NINDS Exploratory/Developmental Projects in Translational Research
NINDS 转化研究探索/开发项目
基本信息
- 批准号:7574330
- 负责人:
- 金额:$ 22.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-15 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acetyl-CoA C-AcetyltransferaseAffectAllelesAnimalsBiochemicalBiogenesisBiological AssayBiological AvailabilityCellsChemicalsClinicalClinical TreatmentClinical TrialsCodeCultured CellsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDevelopmentDiseaseDuchenne muscular dystrophyEngineeringEvaluationFibroblastsFutureGene ExpressionGene Expression ProfilingGenerationsGenesGoalsImmunoblot AnalysisImmunoblottingIndividualInheritedLengthMaintenanceMammalian CellMonitorMorphologyMuscular DystrophiesMutationNeurodegenerative DisordersNonsense CodonNonsense MutationNucleotidesNumbersParentsPatientsPeroxisomal DisordersPharmaceutical PreparationsPhytanic AcidPlasmalogensPortraitsPositioning AttributeProcessProtein ImportProteinsPublic HealthReadingRelative (related person)ReporterReporter GenesRodentSamplingSeriesSkinSpinal Muscular AtrophyStructureTerminator CodonTestingTherapeutic AgentsTherapeutic EffectToxic effectTranscriptTranslational ResearchTranslationsVery Long Chain Fatty Acidanalogbaseinterestnervous system disordernoveloxidationperoxisomeprotein functionresearch clinical testingresponse
项目摘要
DESCRIPTION (provided by applicant): Peroxisomal biogenesis disorders (PBDs) are a group of autosomal recessive neurodegenerative disorders caused by mutations in PEX genes. Our goal is to evaluate the efficacy of a set of newly developed drugs capable of selectively promoting the read-through of premature stop codons (nonsense suppressor compounds) in PEX genes as therapeutic agents for a subset of individuals with PBDs. One such nonsense suppressor drug, PTC-124 is in clinical trials for the treatment of cystic fibrosis and Duchenne's muscular dystrophy cases caused by nonsense mutations in CFTR and DMD, respectively. Another series of analogs based on the parent compound indoprofen have shown nonsense suppressor activity in cell culture assays and have favorable toxicity and bioavailability profiles in rodents. A necessary step in achieving this goal is to determine the ability of these drugs to rescue peroxisome structure and function in cultured cells derived from PBD patients with nonsense mutations in peroxisome assembly (PEX) genes. In this proposal, we will conduct mutational analyses of PEX genes in thirty PBD patients to expand upon a known subset of PBD patients with disease-causing nonsense mutations (Specific Aim 1). Fibroblasts exist from each of these patients which will be used in downstream analyses of peroxisome function. In parallel, we will conduct a series of functional assays on drug-treated cultured fibroblasts derived from eighteen PBD patients with previously identified nonsense mutations in peroxin genes (Specific Aim 2). This includes biochemical, immunolocalization, immunoblot, and reporter gene-based characterization of peroxisome protein function and assembly. Should any of these nonsense suppressor compounds prove effective in rescuing peroxisome function in cultured fibroblasts, we will analyze their off-target effects through microarray-based gene expression profiling of drug-treated cells. Overall, these studies will provide a necessary initial evaluation of the potential efficacy of nonsense mutation suppressor therapies for PBDs prior to our long-term goal of developing therapeutic agents for PBDs that are used in clinical settings.
PUBLIC HEALTH RELEVANCE: Project Narrative We are interested in developing therapies for patients with peroxisome biogenesis disorders (PBD), which are a group of inherited, often fatal, neurological diseases in which there is no current therapy. We will evaluate a series of drugs for their ability to rescue peroxisome functions in skin cells cultured from patients. These drugs have been shown to read through nonsense mutations in two other diseases, and preliminary chemical refinement and animal toxicity studies are in progress. Cellular rescue is a necessary preliminary step for the potential future application of these drugs to treat PBD caused by nonsense mutations.
描述(由申请方提供):过氧化物酶体生物发生疾病(PBD)是一组由PEX基因突变引起的常染色体隐性遗传神经退行性疾病。我们的目标是评估一组新开发的药物的疗效,这些药物能够选择性地促进PEX基因中过早终止密码子(无义抑制化合物)的通读,作为PBD患者亚组的治疗药物。一种这样的无义抑制药物PTC-124正在临床试验中用于治疗分别由CFTR和DMD中的无义突变引起的囊性纤维化和杜氏肌营养不良症病例。基于母体化合物吲哚洛芬的另一系列类似物在细胞培养试验中显示出无义抑制活性,并在啮齿动物中具有良好的毒性和生物利用度。实现这一目标的一个必要步骤是确定这些药物拯救过氧化物酶体组装(PEX)基因无义突变的PBD患者培养细胞中过氧化物酶体结构和功能的能力。在本提案中,我们将对30名PBD患者的PEX基因进行突变分析,以扩展具有致病无义突变的已知PBD患者子集(具体目标1)。这些患者中的每一个都存在成纤维细胞,其将用于过氧化物酶体功能的下游分析。与此同时,我们将对来自18名PBD患者的经药物处理的培养成纤维细胞进行一系列功能测定,这些PBD患者具有先前鉴定的过氧化物酶基因无义突变(特异性目的2)。这包括过氧化物酶体蛋白功能和组装的生物化学、免疫定位、免疫印迹和基于报告基因的表征。如果这些无义抑制剂化合物中的任何一种被证明能有效地挽救培养的成纤维细胞中的过氧化物酶体功能,我们将通过药物处理细胞的基于微阵列的基因表达谱分析来分析它们的脱靶效应。总的来说,这些研究将提供一个必要的初步评估的潜在疗效的无义突变抑制剂治疗PBD之前,我们的长期目标是开发用于临床环境中的PBD的治疗药物。
公共卫生关系:我们有兴趣为患有过氧化物酶体生物合成障碍(PBD)的患者开发治疗方法,PBD是一组遗传性的,通常是致命的神经系统疾病,目前没有治疗方法。我们将评估一系列药物拯救患者皮肤细胞中过氧化物酶体功能的能力。这些药物已被证明可以通过其他两种疾病的无义突变进行阅读,初步的化学改进和动物毒性研究正在进行中。细胞拯救是这些药物未来潜在应用于治疗无义突变引起的PBD的必要的初步步骤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nancy Elise Braverman其他文献
Nancy Elise Braverman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nancy Elise Braverman', 18)}}的其他基金
A Mouse Model Resource for Peroxisome Research
用于过氧化物酶体研究的小鼠模型资源
- 批准号:
10334361 - 财政年份:2022
- 资助金额:
$ 22.77万 - 项目类别:
A Mouse Model Resource for Peroxisome Research
用于过氧化物酶体研究的小鼠模型资源
- 批准号:
10604280 - 财政年份:2022
- 资助金额:
$ 22.77万 - 项目类别:
NINDS Exploratory/Developmental Projects in Translational Research
NINDS 转化研究探索/开发项目
- 批准号:
7917794 - 财政年份:2008
- 资助金额:
$ 22.77万 - 项目类别:
Screening Small Molecules for Rescue of Peroxisome Assembly Defects
筛选小分子以挽救过氧化物酶体组装缺陷
- 批准号:
7136980 - 财政年份:2006
- 资助金额:
$ 22.77万 - 项目类别:
PEX7 AND IT'S ROLE IN THE PATHOGENESIS OF RCDP
PEX7 及其在 RCDP 发病机制中的作用
- 批准号:
6228936 - 财政年份:2001
- 资助金额:
$ 22.77万 - 项目类别:
PEX7 AND IT'S ROLE IN THE PATHOGENESIS OF RCDP
PEX7 及其在 RCDP 发病机制中的作用
- 批准号:
6697287 - 财政年份:2001
- 资助金额:
$ 22.77万 - 项目类别:
PEX7 AND IT'S ROLE IN THE PATHOGENESIS OF RCDP
PEX7 及其在 RCDP 发病机制中的作用
- 批准号:
6629136 - 财政年份:2001
- 资助金额:
$ 22.77万 - 项目类别:
PEX7 AND IT'S ROLE IN THE PATHOGENESIS OF RCDP
PEX7 及其在 RCDP 发病机制中的作用
- 批准号:
6868214 - 财政年份:2001
- 资助金额:
$ 22.77万 - 项目类别:
PEX7 AND IT'S ROLE IN THE PATHOGENESIS OF RCDP
PEX7 及其在 RCDP 发病机制中的作用
- 批准号:
6499153 - 财政年份:2001
- 资助金额:
$ 22.77万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.77万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 22.77万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.77万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 22.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists